Hydromorphone abuse-resistant - Acura Pharmaceuticals

Next Previous
Drug Profile

Hydromorphone abuse-resistant - Acura Pharmaceuticals

Alternative Names: LIMITX Hydromorphone; Limitx™ abuse-resistant hydromorphone; LTX-04

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acura Pharmaceuticals
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 11 Sep 2017 Pharmacokinetics data from a phase I trial (Study 401) in healthy volunteers released by Acura Pharmaceuticals
  • 28 Jun 2017 Pharmacokinetics data from a phase I trial (Study 401) in healthy volunteers released by Acura Pharmaceuticals
  • 18 May 2017 Acura Pharmaceuticals initiates enrolment in a phase I trial for Pain (In volunteers), before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top